CLLS stock forecast, quote, news & analysis
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications... Show more
Why Cellectis (CLLS) Stock Is Down 29% in the Last 30 Days
Key Takeaways
- Cellectis (CLLS) shares fell roughly 29% over the last 30 days, extending a much larger multi-month decline.
- The drop followed a strategic pivot away from its lead blood-cancer CAR-T programs (lasme-cel and eti-cel) toward in vivo gene editing for cardiovascular disease.
- Citizens JMP downgraded the stock to Market Perform, while Barclays moved to Sell with a $1.30 price target, though other analysts kept Buy ratings.
- Management said the restructuring extends the company's cash runway into the second half of 2028.
- Key clinical catalysts, including Phase 1 data for HEAL-101 and HEAL-201, are now pushed out to late 2027 and 2028.
- For more detail on valuation, results, and expectations, explore Cellectis Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioning across the market, visit Trending AI Robots.
Cellectis (CLLS) Company Overview and Market Position
Cellectis S.A. is a clinical-stage biotechnology company headquartered in Paris, France, focused on gene-editing technologies. The company pioneered TALEN gene-editing and has built a portfolio around allogeneic, or "off-the-shelf," chimeric antigen receptor T-cell (CAR-T) therapies, which use immune cells from healthy donors rather than a patient's own cells. Investors have historically followed CLLS for its potential to broaden access to cell therapy and for its partnerships with larger pharmaceutical and biotech companies, including AstraZeneca (AZN), Allogene Therapeutics (ALLO), Servier, and Iovance Biotherapeutics (IOVA). As a clinical-stage company with limited revenue, CLLS's valuation is tied primarily to pipeline milestones and its ability to fund development.
Cellectis (CLLS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Cellectis shares fell from a closing price near $1.48 to roughly $1.05, a decline of about 29%. The move was driven by a steep sell-off that began in mid-September, when the company announced a major strategic shift, and continued through October as the stock set fresh multi-month lows.
The broader quarterly picture is even weaker. Roughly three months ago the stock traded above $2.70, meaning shares have lost more than 60% of their value over that span. The bulk of the damage was concentrated in a single session in mid-September, when the stock fell more than 40%, followed by a further gradual decline into late October.
What Drove CLLS Stock Price in the Last 30 Days
The primary catalyst was Cellectis's announcement that it is discontinuing development of lasme-cel and eti-cel, its two lead allogeneic CAR-T candidates for blood cancers. The company cited improvements in existing cancer treatments and rising competition from bispecific antibodies and newer in vivo CAR-T approaches as reasons the market had become less attractive. Instead, Cellectis is pivoting to in vivo gene editing targeting cardiovascular risk factors, led by HEAL-101 (for very high triglycerides) and HEAL-201 (for elevated lipoprotein cholesterol).
The pivot triggered a wave of analyst reactions. Citizens JMP downgraded the stock to Market Perform from Outperform, noting that the change pushes major clinical catalysts out to late 2027 and 2028. Barclays downgraded Cellectis to Sell with a $1.30 price target, while Robert W. Baird maintained a Buy rating and Wells Fargo reiterated a Hold. The net effect was a sharp repricing as investors digested a longer timeline to clinical data and revenue.
What Drove CLLS Stock Performance Over the Last Quarter
Over the last quarter, Cellectis shares were pressured by a combination of strategic uncertainty and a shrinking near-term catalyst pipeline. Before the pivot, the stock had been trading in a range as investors weighed early-stage cell-therapy data against a limited commercial runway. The decision to abandon the two most advanced cancer programs removed the nearest milestones from the calendar and refocused the company on earlier-stage cardiovascular assets, which are several years away from meaningful readouts. The resulting downgrades and a decline in institutional positioning compounded the selling pressure, leaving the stock near multi-year lows despite roughly $169 million in reported cash reserves.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that currently rank among the platform's top performers. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the most relevant and highest-performing strategies appear in this section. These bots vary widely in approach, trading timeframe, and performance metrics, giving investors a way to compare automated strategies across different market conditions. For traders interested in how quantitative and AI-driven signals are navigating volatile names and shifting sectors, this page offers a useful, neutral starting point for further research.
CLLS Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will likely focus on Cellectis's execution of its new cardiovascular strategy. Near-term attention centers on continued updates to the HEAL-101 and HEAL-201 programs, with early Phase 1 data expected in the second half of 2027 and the first half of 2028, respectively. Quarterly results and cash-burn guidance will also be closely watched, given that the restructuring is intended to extend the runway into the second half of 2028. Broader factors such as competitive developments in in vivo gene editing, regulatory timelines, and the status of the company's existing partnerships with AstraZeneca, Allogene, Servier, and Iovance may also influence sentiment. As with all clinical-stage biotechnology companies, the outcome of ongoing trials and financing conditions remain key variables.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CLLS's RSI Oscillator ascends from oversold territory
The RSI Oscillator for CLLS moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 26 of the 31 cases the stock moved higher. This puts the odds of a move higher at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on CLLS as a result. In 69 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for CLLS just turned positive on October 05, 2026. Looking at past instances where CLLS's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
Following a +30.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in 170 of 216 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CLLS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.649) is normal, around the industry mean (3.162). P/E Ratio (-1.688) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (2.441) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers
Industry Biotechnology